Clinical Trial Update: CCI-779 in Treating Patients With Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating CCI-779 (temsirolimus) in patients with malignant glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• CCI-779 (temsirolimus) (temsirolimus)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED